To evaluate the real-life impact of the immunologic-based decision of TC on the 3- and 6-month relapse rates after TC in bullous pemphigoid.
Retrospective multicentric study included patients followed almost 6 months after TC. Patients were classified according to whether the TC decision was in accordance with the results of ITs performed during the 3 months before TC, despite the results of ITs or without ITs performed.
We included 238 patients. Three months after TC, 36 patients showed relapse: 14 of 95 patients with TC in accordance with IT results (14.7%); 5 of 21 with TC despite ITs (23.8%); and 17 of 122 with TC without ITs (13.9%; P = .5). Six months after TC, the relapse rate was 18.9%, 28.6%, and 18.9% (P = .56), respectively, in the 3 groups.
The retrospective design and the limited follow up.
In real-life practice, in bullous pemphigoid, the 3- and 6-month relapse rates were not significantly reduced with TC decision based on results of ITs as compared with a classic clinical-based decision.
评估基于免疫学的TC决定对大疱性类天疱疮TC后3个月和6个月复发率的现实生活影响。
回顾性多中心研究包括患者在TC后随访近6个月。根据TC决定是否与TC前3个月进行的ITs结果进行分类,尽管有ITs的结果或没有执行ITs。
我们纳入了238名患者。TC后三个月,36例患者出现复发:符合IT结果的95例TC患者中有14例(14.7%);尽管有IT,但仍有TC的21例中有5例(23.8%);122例TC无IT的17例(13.9%;P=5)。TC后六个月,复发率为18.9%,28.6%,和18.9%(P=0.56),分别,在3组。
回顾性设计和有限的随访。
在现实生活中,在大疱性类天疱疮中,与经典的基于临床的决定相比,基于ITs结果的TC决定的3个月和6个月复发率没有显著降低.